Literature DB >> 26244653

Questions of Safety and Fairness Raised as Right-to-Try Movement Gains Steam.

Julie A Jacob.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26244653     DOI： 10.1001/jama.2015.7691

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  9 in total

1.  Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period.

Authors:  Jonathan P Jarow; Steven Lemery; Kevin Bugin; Sean Khozin; Richard Moscicki
Journal:  Ther Innov Regul Sci       Date:  2016-11       Impact factor: 1.778

2.  Impact of Expanded Access on FDA Regulatory Action and Product Labeling.

Authors:  Jonathan P Jarow; Richard Moscicki
Journal:  Ther Innov Regul Sci       Date:  2017-05-03       Impact factor: 1.778

3.  Precision medicine: opportunities, possibilities, and challenges for patients and providers.

Authors:  Samantha A Adams; Carolyn Petersen
Journal:  J Am Med Inform Assoc       Date:  2016-03-14       Impact factor: 7.942

4.  Ethics review in compassionate use.

Authors:  Jan Borysowski; Hans-Jörg Ehni; Andrzej Górski
Journal:  BMC Med       Date:  2017-07-24       Impact factor: 8.775

5.  Oncologists' reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center.

Authors:  Jeremiah Stout; Cambray Smith; Jan Buckner; Alex A Adjei; Mark Wentworth; Jon C Tilburt; Zubin Master
Journal:  PLoS One       Date:  2021-12-17       Impact factor: 3.240

6.  "I Think It's Been Met With a Shrug:" Oncologists' Views Toward and Experiences With Right-to-Try.

Authors:  Cambray Smith; Jeremiah Stout; Alex A Adjei; Jan Buckner; Mark Wentworth; Jon Tilburt; Zubin Master
Journal:  J Natl Cancer Inst       Date:  2021-06-01       Impact factor: 13.506

7.  The Future of Patient Engagement in the Governance of Shared Data.

Authors:  Carolyn Petersen
Journal:  EGEMS (Wash DC)       Date:  2016-03-30

8.  An analysis of common ethical justifications for compassionate use programs for experimental drugs.

Authors:  Kasper Raus
Journal:  BMC Med Ethics       Date:  2016-10-18       Impact factor: 2.652

9.  Expanded Access as a source of real-world data: An overview of FDA and EMA approvals.

Authors:  Tobias B Polak; Joost van Rosmalen; Carin A Uyl-de Groot
Journal:  Br J Clin Pharmacol       Date:  2020-04-07       Impact factor: 4.335
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.